N-アセチルカルノシンは,多臓器系の年齢関連低下を弱め,生存率を向上させる
bioRxiv : the preprint server for biology
|September 5, 2025
まとめ
N-アセチルカルノシンという天然化合物は 老いたマウスの寿命を大幅に延長し 健康状態も改善しました このヒスティジンを含むディペプチド (HCD) 治療法により 年齢に関連した複数の疾患を予防し,健康的な老化への希望の道を示しました
科学分野:
- ゲロントロジーと代謝健康
- 分子生物学と細胞生物学
- 薬理学と治療法
背景:
- N- アセチルカルノシンを含むヒスティジンを含むディペプチド (HCD) は,エルゴジェニックおよび代謝上の利点がある内生代謝産物である.
- 以前の研究では,短期間使用を止めることで,筋縮を防ぐのにN-アセチルカルノシンが有効であることが示されました.
研究 の 目的:
- N-アセチルカルノシンの長期的影響と哺乳類モデルでの生存を調査する.
- N-アセチルカルノシンが老化過程で様々な臓器系に与える影響を総合的に評価する.
主な方法:
- N- アセチルカルノシンを6ヶ月間投与した.
- 年齢に関連する生理学的変化を評価するために,臓器システムの広範な調査が行われました.
- 肥満,心臓機能,血管拡張,筋肉の強さ,骨密度などの主要な健康指標が測定されました.
主要な成果:
- N- アセチルカルノシンによる治療は,雌マウスの幅広い年齢関連疾患を有意に軽減しました.
- N- アセチルカルノシン治療群では生存率が約50%向上した.
- 治療により,肥満,透析機能,血管拡張,筋肉の強さ,骨密度の低下を防ぐことができました.
結論:
- N-アセチルカルノシンは,全身の末期病変の発生を大幅に遅らせ,寿命を延長します.
- 内生代謝物として,N-アセチルカルノシンは健康的な老化を促進する潜在的に安全で効果的な介入です.
- N-アセチルカルノシンをヒトの抗老化療法としてさらなる研究が必要である.
関連する概念動画
Aging
174
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
174
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
The Effect of Aging on Tissues
2.4K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.4K
Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666


